Paper856236
Assessment of response to therapy in advanced breast cancer.
Hayward JL and 5 others. Br J Cancer, 1977. Cited by 387 papers, by iCite.
Cite this record
ConductScience Library. Assessment of response to therapy in advanced breast cancer. Papers, record 856236. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/856236
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Activities of Daily Living | |
| Female | |
| Humans | |
| Neoplasm Metastasis | |
| Research Design |
Source PubMed
Cited by129
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 387 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39955339 | Effect of neoadjuvant chemotherapy on CD14 + CD16 + monocytes and soluble CD163 in Egyptian breast cancer patients. | Sci Rep | 2025 | https://conductscience.org/library/papers/39955339 | PubMed |
| 39022246 | 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the localization of the lesions in the osteogenic region of breast cancer bone metastases after therapy. | Quant Imaging Med Surg | 2024 | https://conductscience.org/library/papers/39022246 | PubMed |
| 36961572 | Computed tomography density changes of bone metastases after concomitant denosumab. | Skeletal Radiol | 2023 | https://conductscience.org/library/papers/36961572 | PubMed |
| 36092784 | Breast MRI Tumor Automatic Segmentation and Triple-Negative Breast Cancer Discrimination Algorithm Based on Deep Learning. | Comput Math Methods Med | 2022 | https://conductscience.org/library/papers/36092784 | PubMed |
| 35751095 | DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. | Breast Cancer Res | 2022 | https://conductscience.org/library/papers/35751095 | PubMed |
| 35419519 | The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab. | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/35419519 | PubMed |
| 33226492 | Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray. | Breast Cancer Res Treat | 2021 | https://conductscience.org/library/papers/33226492 | PubMed |
| 33037978 | Breast tumour cell subpopulations with expression of the MYC and OCT4 proteins. | J Mol Histol | 2020 | https://conductscience.org/library/papers/33037978 | PubMed |
| 32154098 | Bone metastases in thyroid cancer. | J Bone Oncol | 2020 | https://conductscience.org/library/papers/32154098 | PubMed |
| 30050402 | Silencing miR-150 Ameliorates Experimental Autoimmune Encephalomyelitis. | Front Neurosci | 2018 | https://conductscience.org/library/papers/30050402 | PubMed |
| 28522855 | Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. | Sci Rep | 2017 | https://conductscience.org/library/papers/28522855 | PubMed |
| 27399922 | EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. | Rev Bras Ginecol Obstet | 2016 | https://conductscience.org/library/papers/27399922 | PubMed |
| 27106355 | Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study. | Croat Med J | 2016 | https://conductscience.org/library/papers/27106355 | PubMed |
| 26943585 | Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel. | Oncotarget | 2016 | https://conductscience.org/library/papers/26943585 | PubMed |
| 26909251 | Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. | J Bone Oncol | 2012 | https://conductscience.org/library/papers/26909251 | PubMed |
| 26657294 | Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/26657294 | PubMed |
| 26004085 | Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. | Mol Oncol | 2015 | https://conductscience.org/library/papers/26004085 | PubMed |
| 24396494 | Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. | J Cancer | 2014 | https://conductscience.org/library/papers/24396494 | PubMed |
| 24350285 | Usefulness of traditional serum biomarkers for management of breast cancer patients. | Biomed Res Int | 2013 | https://conductscience.org/library/papers/24350285 | PubMed |
| 23849542 | GPER-1 acts as a tumor suppressor in ovarian cancer. | J Ovarian Res | 2013 | https://conductscience.org/library/papers/23849542 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/856236
GET https://conductscience.org/api/papers/v1/856236/cited_by?page=2